Global Cardioselective Beta Blockers Market Growth 2025-2031

Publication ID:

LPI04255172

Publication Date:

April 23, 2025

Pages:

131

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Cardioselective Beta Blockers market size is predicted to grow from US$ 7220 million in 2025 to US$ 10430 million in 2031; it is expected to grow at a CAGR of 6.3% from 2025 to 2031.
Cardioselective beta blockers intercept the activation of beta-1 adrenergic receptors present at the nerve endings of the sympathetic nervous system. This eventually results in diminished activity of the heart, such as a reduction in systolic pressure, heart rate and cardiac contractility. Cardioselective agents have a better affinity for 尾1-adrenergic receptors located in the heart, whereas nonselective agents work on 尾1-adrenergic receptors and 尾2-adrenergic receptors located in bronchial musculature.
Widespread Demand for Metoprolol for Cardiovascular Diseases: Treatment of Cardiovascular Diseases with Metoprolol presents a huge revenue opportunity for companies in the market. The metoprolol segment holds the dominant market share in pharmaceuticals in 2022. Outstanding safety and efficacy, ease of administration, and affordability are key factors for the widespread utilization of this class of drugs in the treatment of heart failure and hypertension. Surging demand for metoprolol over the past few years is likely to drive the market in the near future.
Development of drug delivery technologies to improve the safety and efficacy of cardioselective beta-blockers: Ongoing research into the mechanism of action of beta-blockers enables the company to develop drugs with unique pharmacological profiles. This may facilitate the off-label use of beta-blockers and provide new business opportunities for drug manufacturers in the near future. In addition, pharmaceutical companies are working to develop beta-blockers with improved routes of administration to reduce their common side effects and enhance the targeting of these drugs in the treatment of angina, cardiac arrhythmias, and chronic heart failure.
The 鈥淐ardioselective Beta Blockers Industry Forecast鈥� looks at past sales and reviews total world Cardioselective Beta Blockers sales in 2024, providing a comprehensive analysis by region and market sector of projected Cardioselective Beta Blockers sales for 2025 through 2031. With Cardioselective Beta Blockers sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cardioselective Beta Blockers industry.
This Insight Report provides a comprehensive analysis of the global Cardioselective Beta Blockers landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cardioselective Beta Blockers portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Cardioselective Beta Blockers market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cardioselective Beta Blockers and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cardioselective Beta Blockers.
This report presents a comprehensive overview, market shares, and growth opportunities of Cardioselective Beta Blockers market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Oral
Injection
Segmentation by Application:
Hospitals
Specialty Clinics
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
F. Hoffmann-La Roche Ltd
Fresenius Kabi AG
Pfizer Inc
Bayer AG
GSK Plc
Sanofi
Novartis AG
Mylan N.V
Teva Pharmaceutical Industries Ltd
Zydus Group
Viatris Inc
Merck & Co., Inc
Recordati S.p.A
Pierre Fabre Group
AbbVie, Inc
AstraZeneca
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cardioselective Beta Blockers market?
What factors are driving Cardioselective Beta Blockers market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cardioselective Beta Blockers market opportunities vary by end market size?
How does Cardioselective Beta Blockers break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cardioselective Beta Blockers Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Cardioselective Beta Blockers by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Cardioselective Beta Blockers by Country/Region, 2020, 2024 & 2031
2.2 Cardioselective Beta Blockers Segment by Type
2.2.1 Oral
2.2.2 Injection
2.3 Cardioselective Beta Blockers Sales by Type
2.3.1 Global Cardioselective Beta Blockers Sales Market Share by Type (2020-2025)
2.3.2 Global Cardioselective Beta Blockers Revenue and Market Share by Type (2020-2025)
2.3.3 Global Cardioselective Beta Blockers Sale Price by Type (2020-2025)
2.4 Cardioselective Beta Blockers Segment by Application
2.4.1 Hospitals
2.4.2 Specialty Clinics
2.4.3 Other
2.5 Cardioselective Beta Blockers Sales by Application
2.5.1 Global Cardioselective Beta Blockers Sale Market Share by Application (2020-2025)
2.5.2 Global Cardioselective Beta Blockers Revenue and Market Share by Application (2020-2025)
2.5.3 Global Cardioselective Beta Blockers Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Cardioselective Beta Blockers Breakdown Data by Company
3.1.1 Global Cardioselective Beta Blockers Annual Sales by Company (2020-2025)
3.1.2 Global Cardioselective Beta Blockers Sales Market Share by Company (2020-2025)
3.2 Global Cardioselective Beta Blockers Annual Revenue by Company (2020-2025)
3.2.1 Global Cardioselective Beta Blockers Revenue by Company (2020-2025)
3.2.2 Global Cardioselective Beta Blockers Revenue Market Share by Company (2020-2025)
3.3 Global Cardioselective Beta Blockers Sale Price by Company
3.4 Key Manufacturers Cardioselective Beta Blockers Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cardioselective Beta Blockers Product Location Distribution
3.4.2 Players Cardioselective Beta Blockers Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Cardioselective Beta Blockers by Geographic Region
4.1 World Historic Cardioselective Beta Blockers Market Size by Geographic Region (2020-2025)
4.1.1 Global Cardioselective Beta Blockers Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Cardioselective Beta Blockers Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Cardioselective Beta Blockers Market Size by Country/Region (2020-2025)
4.2.1 Global Cardioselective Beta Blockers Annual Sales by Country/Region (2020-2025)
4.2.2 Global Cardioselective Beta Blockers Annual Revenue by Country/Region (2020-2025)
4.3 Americas Cardioselective Beta Blockers Sales Growth
4.4 APAC Cardioselective Beta Blockers Sales Growth
4.5 Europe Cardioselective Beta Blockers Sales Growth
4.6 Middle East & Africa Cardioselective Beta Blockers Sales Growth
5 Americas
5.1 Americas Cardioselective Beta Blockers Sales by Country
5.1.1 Americas Cardioselective Beta Blockers Sales by Country (2020-2025)
5.1.2 Americas Cardioselective Beta Blockers Revenue by Country (2020-2025)
5.2 Americas Cardioselective Beta Blockers Sales by Type (2020-2025)
5.3 Americas Cardioselective Beta Blockers Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cardioselective Beta Blockers Sales by Region
6.1.1 APAC Cardioselective Beta Blockers Sales by Region (2020-2025)
6.1.2 APAC Cardioselective Beta Blockers Revenue by Region (2020-2025)
6.2 APAC Cardioselective Beta Blockers Sales by Type (2020-2025)
6.3 APAC Cardioselective Beta Blockers Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Cardioselective Beta Blockers by Country
7.1.1 Europe Cardioselective Beta Blockers Sales by Country (2020-2025)
7.1.2 Europe Cardioselective Beta Blockers Revenue by Country (2020-2025)
7.2 Europe Cardioselective Beta Blockers Sales by Type (2020-2025)
7.3 Europe Cardioselective Beta Blockers Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cardioselective Beta Blockers by Country
8.1.1 Middle East & Africa Cardioselective Beta Blockers Sales by Country (2020-2025)
8.1.2 Middle East & Africa Cardioselective Beta Blockers Revenue by Country (2020-2025)
8.2 Middle East & Africa Cardioselective Beta Blockers Sales by Type (2020-2025)
8.3 Middle East & Africa Cardioselective Beta Blockers Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cardioselective Beta Blockers
10.3 Manufacturing Process Analysis of Cardioselective Beta Blockers
10.4 Industry Chain Structure of Cardioselective Beta Blockers
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cardioselective Beta Blockers Distributors
11.3 Cardioselective Beta Blockers Customer
12 World Forecast Review for Cardioselective Beta Blockers by Geographic Region
12.1 Global Cardioselective Beta Blockers Market Size Forecast by Region
12.1.1 Global Cardioselective Beta Blockers Forecast by Region (2026-2031)
12.1.2 Global Cardioselective Beta Blockers Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Cardioselective Beta Blockers Forecast by Type (2026-2031)
12.7 Global Cardioselective Beta Blockers Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 F. Hoffmann-La Roche Ltd
13.1.1 F. Hoffmann-La Roche Ltd Company Information
13.1.2 F. Hoffmann-La Roche Ltd Cardioselective Beta Blockers Product Portfolios and Specifications
13.1.3 F. Hoffmann-La Roche Ltd Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.1.5 F. Hoffmann-La Roche Ltd Latest Developments
13.2 Fresenius Kabi AG
13.2.1 Fresenius Kabi AG Company Information
13.2.2 Fresenius Kabi AG Cardioselective Beta Blockers Product Portfolios and Specifications
13.2.3 Fresenius Kabi AG Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Fresenius Kabi AG Main Business Overview
13.2.5 Fresenius Kabi AG Latest Developments
13.3 Pfizer Inc
13.3.1 Pfizer Inc Company Information
13.3.2 Pfizer Inc Cardioselective Beta Blockers Product Portfolios and Specifications
13.3.3 Pfizer Inc Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Pfizer Inc Main Business Overview
13.3.5 Pfizer Inc Latest Developments
13.4 Bayer AG
13.4.1 Bayer AG Company Information
13.4.2 Bayer AG Cardioselective Beta Blockers Product Portfolios and Specifications
13.4.3 Bayer AG Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Bayer AG Main Business Overview
13.4.5 Bayer AG Latest Developments
13.5 GSK Plc
13.5.1 GSK Plc Company Information
13.5.2 GSK Plc Cardioselective Beta Blockers Product Portfolios and Specifications
13.5.3 GSK Plc Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 GSK Plc Main Business Overview
13.5.5 GSK Plc Latest Developments
13.6 Sanofi
13.6.1 Sanofi Company Information
13.6.2 Sanofi Cardioselective Beta Blockers Product Portfolios and Specifications
13.6.3 Sanofi Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Sanofi Main Business Overview
13.6.5 Sanofi Latest Developments
13.7 Novartis AG
13.7.1 Novartis AG Company Information
13.7.2 Novartis AG Cardioselective Beta Blockers Product Portfolios and Specifications
13.7.3 Novartis AG Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Novartis AG Main Business Overview
13.7.5 Novartis AG Latest Developments
13.8 Mylan N.V
13.8.1 Mylan N.V Company Information
13.8.2 Mylan N.V Cardioselective Beta Blockers Product Portfolios and Specifications
13.8.3 Mylan N.V Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Mylan N.V Main Business Overview
13.8.5 Mylan N.V Latest Developments
13.9 Teva Pharmaceutical Industries Ltd
13.9.1 Teva Pharmaceutical Industries Ltd Company Information
13.9.2 Teva Pharmaceutical Industries Ltd Cardioselective Beta Blockers Product Portfolios and Specifications
13.9.3 Teva Pharmaceutical Industries Ltd Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.9.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.10 Zydus Group
13.10.1 Zydus Group Company Information
13.10.2 Zydus Group Cardioselective Beta Blockers Product Portfolios and Specifications
13.10.3 Zydus Group Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Zydus Group Main Business Overview
13.10.5 Zydus Group Latest Developments
13.11 Viatris Inc
13.11.1 Viatris Inc Company Information
13.11.2 Viatris Inc Cardioselective Beta Blockers Product Portfolios and Specifications
13.11.3 Viatris Inc Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Viatris Inc Main Business Overview
13.11.5 Viatris Inc Latest Developments
13.12 Merck & Co., Inc
13.12.1 Merck & Co., Inc Company Information
13.12.2 Merck & Co., Inc Cardioselective Beta Blockers Product Portfolios and Specifications
13.12.3 Merck & Co., Inc Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Merck & Co., Inc Main Business Overview
13.12.5 Merck & Co., Inc Latest Developments
13.13 Recordati S.p.A
13.13.1 Recordati S.p.A Company Information
13.13.2 Recordati S.p.A Cardioselective Beta Blockers Product Portfolios and Specifications
13.13.3 Recordati S.p.A Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Recordati S.p.A Main Business Overview
13.13.5 Recordati S.p.A Latest Developments
13.14 Pierre Fabre Group
13.14.1 Pierre Fabre Group Company Information
13.14.2 Pierre Fabre Group Cardioselective Beta Blockers Product Portfolios and Specifications
13.14.3 Pierre Fabre Group Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Pierre Fabre Group Main Business Overview
13.14.5 Pierre Fabre Group Latest Developments
13.15 AbbVie, Inc
13.15.1 AbbVie, Inc Company Information
13.15.2 AbbVie, Inc Cardioselective Beta Blockers Product Portfolios and Specifications
13.15.3 AbbVie, Inc Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 AbbVie, Inc Main Business Overview
13.15.5 AbbVie, Inc Latest Developments
13.16 AstraZeneca
13.16.1 AstraZeneca Company Information
13.16.2 AstraZeneca Cardioselective Beta Blockers Product Portfolios and Specifications
13.16.3 AstraZeneca Cardioselective Beta Blockers Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 AstraZeneca Main Business Overview
13.16.5 AstraZeneca Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂